Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EVO 
Evotec SE ADR (EVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: EVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.04
1 Year Target Price $6.04
| 1 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.35% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 6.04 |
Price to earnings Ratio - | 1Y Target Price 6.04 | ||
Volume (30-day avg) 6 | Beta 1.06 | 52 Weeks Range 2.84 - 5.64 | Updated Date 09/16/2025 |
52 Weeks Range 2.84 - 5.64 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.01% | Operating Margin (TTM) -16.7% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -16.75% |
Valuation
Trailing PE - | Forward PE 59.88 | Enterprise Value 946017889 | Price to Sales(TTM) 1.6 |
Enterprise Value 946017889 | Price to Sales(TTM) 1.6 | ||
Enterprise Value to Revenue 1.04 | Enterprise Value to EBITDA -21.37 | Shares Outstanding 355198016 | Shares Floating 130516727 |
Shares Outstanding 355198016 | Shares Floating 130516727 | ||
Percent Insiders - | Percent Institutions 2.72 |
Upturn AI SWOT
Evotec SE ADR
Company Overview
History and Background
Evotec SE was founded in 1993 in Hamburg, Germany. Initially focused on high-throughput screening, it evolved into a drug discovery alliance and development company. Over the years, Evotec has grown through strategic acquisitions and partnerships, expanding its capabilities and global presence.
Core Business Areas
- EVT Execute: Provides fully integrated drug discovery solutions, from target identification to preclinical development. This includes hit identification, lead optimization, and compound profiling.
- EVT Innovate: Focuses on the discovery and development of novel therapeutic candidates. This segment leverages Evotec's internal expertise and partnerships to create and advance proprietary drug programs.
- Just - Evotec Biologics: Offers comprehensive services for the development and manufacture of biologics. This includes cell line development, process optimization, and GMP manufacturing.
Leadership and Structure
Evotec SE is led by CEO Christian Wojczewski. The company has a supervisory board that oversees management. The organizational structure is divided into functional areas and business segments, with a focus on collaboration and innovation.
Top Products and Market Share
Key Offerings
- Integrated Drug Discovery Solutions: Provides end-to-end drug discovery services to pharmaceutical and biotechnology companies. Market share data is difficult to pinpoint exactly for Evotec specifically, but the global drug discovery market is highly competitive. Competitors include Charles River Laboratories (CRL), WuXi AppTec, and Labcorp (LH).
- Biologics Development and Manufacturing: Offers services for the development and manufacturing of biologic drugs, including cell line development, process optimization, and GMP manufacturing. Revenue is not explicitly provided. Competitors include Lonza, Samsung Biologics, and Thermo Fisher Scientific (TMO).
- Proprietary Drug Programs: Discovery and development of their own internal pipeline drug programs. No marketshare data because it is their own product development. Competitors are any large Pharma.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are driven by the need for new and improved therapies. The drug discovery market is experiencing growth due to technological advancements, increasing R&D spending, and the rise of chronic diseases. The biologics market is expanding rapidly due to the success of antibody therapies and other biologics.
Positioning
Evotec is positioned as a leading provider of integrated drug discovery solutions and biologics development services. Its competitive advantages include its comprehensive capabilities, experienced team, and strategic partnerships.
Total Addressable Market (TAM)
The global drug discovery market is expected to reach hundreds of billions USD. Evotec is well-positioned to capture a significant share of this market through its comprehensive offerings and global presence.
Upturn SWOT Analysis
Strengths
- Comprehensive drug discovery platform
- Strong scientific expertise
- Strategic partnerships with pharmaceutical companies
- Global presence
- Integrated biologics development capabilities
Weaknesses
- Reliance on external funding for drug development
- Exposure to competition in the CRO/CDMO market
- Dependence on success of partnered programs
- Small-cap compared to Big-Pharma
Opportunities
- Growing demand for drug discovery services
- Expansion into new therapeutic areas
- Increasing adoption of biologics
- Strategic acquisitions to expand capabilities
- Further investment in AI-powered drug discovery
Threats
- Increased competition in the CRO/CDMO market
- Regulatory changes impacting drug development
- Economic downturn affecting R&D spending
- Failure of partnered drug programs
- Unsuccessful acquisitions
Competitors and Market Share
Key Competitors
- Charles River Laboratories (CRL)
- WuXi AppTec
- Lonza
Competitive Landscape
Evotec competes with other CROs/CDMOs based on capabilities, price, and geographic reach. They benefit from a broad integrated platform and good scientific reputation. They are disadvantaged due to being a smaller organization than some larger competitors.
Major Acquisitions
Rigeneron Biologics, Inc.
- Year: 2022
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expanded Evotec's biologics manufacturing capabilities and capacity, particularly in mammalian cell culture, and providing access to Rigeneron's proprietary technologies. (USD 90M)
Growth Trajectory and Initiatives
Historical Growth: Evotec has experienced growth through strategic acquisitions and partnerships and also through its pipeline development.
Future Projections: Future growth projections would require access to analyst forecasts and Evotec's management guidance.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand capabilities in biologics and cell therapies, expansion of AI drug discovery platform.
Summary
Evotec is a well-positioned drug discovery and development company with a comprehensive platform and strategic partnerships. Its strengths lie in its integrated approach and scientific expertise. However, the company faces competition and relies on external funding and pipeline successes. Recent acquisitions should bolster its growth prospects, but the company must navigate a dynamic and competitive market to achieve its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Evotec SE Website
- Company Press Releases
- Market Research Reports (e.g., Evaluate Pharma, GlobalData)
- Analyst Reports
- Publicly Available Financial Data (SEC filings when applicable). Note, this requires further research to include actual numbers.
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It should not be considered financial advice. Market share estimates are approximate and may vary depending on the source. The AI-based rating is for informational purposes only and should not be the sole basis for investment decisions. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evotec SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-12-04 | CEO & Management Board Member Dr. Christian Wojczewski Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 4759 | Website https://www.evotec.com |
Full time employees 4759 | Website https://www.evotec.com | ||
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.